Steroid Hormone Receptors in Endometrial Stromal Sarcomas: <i>A Biochemical and Immunohistochemical Study</i>

Sabini, G.; Chumas, John; Mann, William J.

doi:10.1093/ajcp/97.3.381

Cited by 63 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,11 Immunohistochemical study has been useful in differential diagnosis: 'Low-grade' ESS commonly expresses estrogen and/or progesterone receptors, but 'high-grade' ESS does not express these receptors. 12 All of the 'low-grade' ESS show CD 10 expression by immunohistochemistry 13,14 and 'high-grade' ESS in only 67% of cases. 13 Although our present case does not show direct progression from endometriosis, it satisfies criteria as a malignant transformation of endometriosis and, as newly defined, can be referred to as ESS malignancy.…”

Section: Discussionmentioning

confidence: 99%

Endometrial stromal sarcoma associated with extrauterine endometriosis: a case report and literature review

Park

Lee

Kwon

et al. 2008

Korean J Gynecol Oncol

View full text Add to dashboard Cite

Endometrial stromal sarcoma (ESS) that arises from extrauterine endometriosis is a rare form of malignancy. We report the case of a 37-year-old ESS patient with extrauterine endometriosis who was treated with ifosfamide/cisplatin chemotherapy. A woman presented with epigastric pain and abdominal distension. ) and cisplatin (50 mg/m 2 ) (IP)] were administered. After a six-month of disease-free interval, recurrent ESS developed in the pelvic cavity and in both lung fields. Megace medication decreased tumor marker CA-125 for six weeks. However, the patient expired sixteen months after the cytoreductive surgery. ESS associated with extrauterine endometriosis showed response to IP chemotherapy and megace.

show abstract

Section: Discussionmentioning

confidence: 99%

Endometrial stromal sarcoma associated with extrauterine endometriosis: a case report and literature review

Park

Lee

Kwon

et al. 2008

Korean J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…A few studies have demonstrated nuclear staining for AR in normal glands, endometrial stromal cells, and in endometrioid adenocarcinomas [3]. Several previous studies revealed expression of ER and PR in a high percentage of endometrial stromal sarcoma [13,21,22,29]. However, to the best of our knowledge, the issue of AR expression in benign and malignant endometrial stromal neoplasms has not been examined previously.…”

Section: Discussionmentioning

confidence: 99%

“…Several previous biochemical and immunohistochemical studies [13,21,22,29] have shown that uterine stromal neoplasms, particularly low-grade ESS, often express estrogen and progesterone receptors (ER, PR). Studies have also revealed that therapy with progestational agents is an important adjunct to surgical treatment in cases of low-grade ESS [7].…”

Section: Introductionmentioning

confidence: 99%

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

et al. 2004

View full text Add to dashboard Cite

Several studies have shown that endometrial stromal neoplasms express estrogen and progesterone receptors (ER, PR). To our knowledge, the presence or absence of androgen receptors (AR) in these rare uterine neoplasms has not been investigated. Tumors ( n=20)-3 endometrial stromal nodules, 14 low-grade endometrial stromal sarcomas (ESS, low grade), and 3 high-grade endometrial sarcomas (undifferentiated endometrial sarcoma, UES)-were studied. Immunohistochemical analyses for ER, PR, and AR were performed on formalin-fixed, paraffin-embedded archival material. Positive immunoreactions for ER and PR were observed in 14 (70%) and 17 (85%) cases, respectively. Furthermore, 9 cases (45%) were positive for AR. Among 17 ESS and UES cases, 7 (41%) revealed positivity for AR. Two of three benign stromal nodules were also positive for AR. Moreover, one of the three high-grade sarcomas (undifferentiated endometrial sarcoma) was negative for both ER and PR, but showed positive reaction for AR. In summary, ARs are expressed in 45% of endometrial stromal neoplasms. In addition to determination of ER and PR, the results of immunohistochemical examination of AR in these rare uterine tumors may have some impact on the postoperative management of the patients.

show abstract

“…Some studies contain reports on the presence of steroid hormone receptors in endometrial stromal sarcomas (Sabini et al 1992;Navarro et al 1992) and record that the absence of receptors correlates with high-grade tumours. PDGF is a potent mitogen for a variety of cell types, in particular connective-tissue-derived cells in vitro (Smits et al 1992).…”

Section: Discussionmentioning

confidence: 99%

“…The expression of a receptor to the epidermal growth factor (EGF) has been studied in sarcomas (Duda et al 1993). The in¯uence of progesterone has been examined in endometrial stromal sarcomas, where the presence of progesterone receptors has been demonstrated (Sabini et al 1992;Navarro et al 1992). Dutkowsky et al studied the in¯uence of fetal thyroid hormone (RT3) on sarcoma cell lines and demonstrated a stimulatory eect of this hormone on several of them (Dutkowsky et al 1993).…”

Section: Introductionmentioning

confidence: 99%

The in vitro influence of eight hormones and growth factors on the proliferation of eight sarcoma cell lines

Remmelink

Decaestecker

Darro

et al. 1998

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

Little is known about the regulation of sarcoma proliferation by hormones and/or growth factors. We therefore characterised the in vitro proliferative influence on eight sarcoma cell lines of the platelet-derived growth factor, the insulin-like growth factor 1, triiodothyronine, the epidermal growth factor, the luteinising-hormone-releasing hormone, progesterone, gastrin and 17 beta-oestradiol. The influence of the different factors on the proliferation of sarcoma cell lines was measured by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test. Two culture media were studied: (1) a nutritionally poor medium containing 2% of fetal calf serum and (2) a nutritionally rich one containing 5% or 10% FCS both with and without the addition of non-essential amino acids. The results were analysed either by conventional statistical analyses or by a classification method based on a decision-tree approach developed in Machine Learning. This latter method was also compared to other classifiers (such as logistic regression and k nearest neighbours) with respect to its accuracy of classification. Monovariate statistical analysis showed that each of the eight cell lines exhibited sensitivity to at least one factor, and each factor significantly modified the proliferation of five or six of the eight cell lines under study. Of these eight lines one of fibrosarcoma origin was the most "factor-sensitive". Decision-tree-related data analysis enabled the specific pattern of factor sensitivity to be characterised for the three histological types of cell line under study. The effects of hormone and growth factors are significantly influenced by the type of culture medium used. The method used appeared to be an accurate classifier for the kind of data analysed. Sarcoma proliferation can be modulated, at least in vitro, by various hormones and growth factors, and the proliferation of each histopathological type exhibited a distinct sensitivity to different hormone and/or growth-factors.

show abstract

Steroid Hormone Receptors in Endometrial Stromal Sarcomas: A Biochemical and Immunohistochemical Study

Cited by 63 publications

References 0 publications

Endometrial stromal sarcoma associated with extrauterine endometriosis: a case report and literature review

Endometrial stromal sarcoma associated with extrauterine endometriosis: a case report and literature review

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

The in vitro influence of eight hormones and growth factors on the proliferation of eight sarcoma cell lines

Contact Info

Product

Resources

About